Which has stronger valuation and earnings, PVLA or EIKN?

Palvella Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palvella Therapeutics N/A N/A -$41.72M -$4.17 N/A Eikon Therapeutics N/A N/A N/A -$2.46 N/A

Is PVLA or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -56.87% -42.50% Eikon Therapeutics N/A N/A N/A

Does the media refer more to PVLA or EIKN?

In the previous week, Palvella Therapeutics had 8 more articles in the media than Eikon Therapeutics. MarketBeat recorded 11 mentions for Palvella Therapeutics and 3 mentions for Eikon Therapeutics. Palvella Therapeutics' average media sentiment score of 1.01 beat Eikon Therapeutics' score of 0.62 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AMLX or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -55.69% -50.73% Eikon Therapeutics N/A N/A N/A

Does the media refer more to AMLX or EIKN?

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Eikon Therapeutics. MarketBeat recorded 7 mentions for Amylyx Pharmaceuticals and 3 mentions for Eikon Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 1.01 beat Eikon Therapeutics' score of 0.62 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GLUE or EIKN?

In the previous week, Monte Rosa Therapeutics and Monte Rosa Therapeutics both had 3 articles in the media. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Eikon Therapeutics' score of 0.62 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EIKN or ADMA?

In the previous week, ADMA Biologics had 33 more articles in the media than Eikon Therapeutics. MarketBeat recorded 36 mentions for ADMA Biologics and 3 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.62 beat ADMA Biologics' score of 0.07 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 1 Very Positive mention(s) 1 Positive mention(s) 33 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EIKN or RAPP more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Rapport Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Rapport Therapeutics N/A -24.78% -23.44%

Does the media favor EIKN or RAPP?

In the previous week, Eikon Therapeutics and Eikon Therapeutics both had 3 articles in the media. Rapport Therapeutics' average media sentiment score of 0.85 beat Eikon Therapeutics' score of 0.62 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eikon Therapeutics (EIKN) Competitors

$8.90 -0.72 (-7.48%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$8.90 +0.00 (+0.06%)

As of 07/24/2026 07:34 PM Eastern

Compare

EIKN vs. PVLA, AMLX, GLUE, ADMA, and RAPP

Should you buy Eikon Therapeutics stock or one of its competitors? MarketBeat compares Eikon Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eikon Therapeutics include Palvella Therapeutics (PVLA), Amylyx Pharmaceuticals (AMLX), Monte Rosa Therapeutics (GLUE), ADMA Biologics (ADMA), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry.

How does Eikon Therapeutics compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Eikon Therapeutics' return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Eikon Therapeutics	N/A	N/A	N/A

Palvella Therapeutics currently has a consensus target price of $199.53, suggesting a potential upside of 44.58%. Eikon Therapeutics has a consensus target price of $25.20, suggesting a potential upside of 183.15%. Given Eikon Therapeutics' higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Palvella Therapeutics had 8 more articles in the media than Eikon Therapeutics. MarketBeat recorded 11 mentions for Palvella Therapeutics and 3 mentions for Eikon Therapeutics. Palvella Therapeutics' average media sentiment score of 1.01 beat Eikon Therapeutics' score of 0.62 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.1% of Palvella Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Palvella Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	N/A	N/A	-$41.72M	-$4.17	N/A
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A

Summary

Palvella Therapeutics beats Eikon Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Eikon Therapeutics compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Eikon Therapeutics. MarketBeat recorded 7 mentions for Amylyx Pharmaceuticals and 3 mentions for Eikon Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 1.01 beat Eikon Therapeutics' score of 0.62 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals presently has a consensus price target of $24.63, indicating a potential upside of 33.76%. Eikon Therapeutics has a consensus price target of $25.20, indicating a potential upside of 183.15%. Given Eikon Therapeutics' higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Eikon Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	23.43	-$144.74M	-$1.50	N/A
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eikon Therapeutics' return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Eikon Therapeutics	N/A	N/A	N/A

Summary

Amylyx Pharmaceuticals beats Eikon Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Eikon Therapeutics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

In the previous week, Monte Rosa Therapeutics and Monte Rosa Therapeutics both had 3 articles in the media. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Eikon Therapeutics' score of 0.62 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	15.56	-$38.63M	-$1.48	N/A
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Monte Rosa Therapeutics currently has a consensus target price of $33.33, indicating a potential upside of 46.33%. Eikon Therapeutics has a consensus target price of $25.20, indicating a potential upside of 183.15%. Given Eikon Therapeutics' higher possible upside, analysts plainly believe Eikon Therapeutics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Eikon Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Eikon Therapeutics' return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
Eikon Therapeutics	N/A	N/A	N/A

Summary

Monte Rosa Therapeutics beats Eikon Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Eikon Therapeutics compare to ADMA Biologics?

Eikon Therapeutics (NASDAQ:EIKN) and ADMA Biologics (NASDAQ:ADMA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

75.7% of ADMA Biologics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ADMA Biologics has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A
ADMA Biologics	$510.17M	3.76	$146.93M	$0.68	12.16

Eikon Therapeutics currently has a consensus price target of $25.20, suggesting a potential upside of 183.15%. ADMA Biologics has a consensus price target of $18.67, suggesting a potential upside of 125.72%. Given Eikon Therapeutics' higher possible upside, equities analysts clearly believe Eikon Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

ADMA Biologics has a net margin of 32.43% compared to Eikon Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Eikon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
ADMA Biologics	32.43%	39.98%	28.08%

In the previous week, ADMA Biologics had 33 more articles in the media than Eikon Therapeutics. MarketBeat recorded 36 mentions for ADMA Biologics and 3 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.62 beat ADMA Biologics' score of 0.07 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	1 Very Positive mention(s)	1 Positive mention(s)	33 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ADMA Biologics beats Eikon Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Eikon Therapeutics compare to Rapport Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Eikon Therapeutics has higher earnings, but lower revenue than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A
Rapport Therapeutics	$20M	97.28	-$111.48M	-$2.60	N/A

In the previous week, Eikon Therapeutics and Eikon Therapeutics both had 3 articles in the media. Rapport Therapeutics' average media sentiment score of 0.85 beat Eikon Therapeutics' score of 0.62 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics presently has a consensus target price of $25.20, indicating a potential upside of 183.15%. Rapport Therapeutics has a consensus target price of $57.86, indicating a potential upside of 42.23%. Given Eikon Therapeutics' higher probable upside, equities research analysts plainly believe Eikon Therapeutics is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Eikon Therapeutics' return on equity of 0.00% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Rapport Therapeutics	N/A	-24.78%	-23.44%

Summary

Eikon Therapeutics and Rapport Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Eikon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EIKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EIKN vs. The Competition

Export

Metric	Eikon Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$481.84M	$640.25M	$7.24B	$12.28B
Dividend Yield	N/A	N/A	40.99%	9.79%
P/E Ratio	-3.62	N/A	23.62	23.71
Price / Sales	N/A	60.23	160.99	75.28
Price / Cash	N/A	N/A	165.01	59.64
Price / Book	N/A	2.52	12.77	6.07
Net Income	N/A	-$75.73M	$120.21M	$331.99M
7 Day Performance	-8.90%	-1.46%	-0.98%	-0.63%
1 Month Performance	-9.64%	12.75%	-2.00%	-2.00%
1 Year Performance	N/A	-77.48%	9.75%	13.62%

Eikon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EIKN Eikon Therapeutics	2.2362 of 5 stars	$8.90 -7.5%	$25.20 +183.1%	N/A	$481.84M	N/A	N/A	384
PVLA Palvella Therapeutics	3.6354 of 5 stars	$143.25 +15.4%	$199.53 +39.3%	+257.3%	$2.06B	$42.81M	N/A	N/A	Positive News Analyst Forecast
AMLX Amylyx Pharmaceuticals	3.9568 of 5 stars	$18.25 +4.6%	$24.63 +35.0%	+121.8%	$2.03B	$87.37M	N/A	200	Positive News
GLUE Monte Rosa Therapeutics	2.9179 of 5 stars	$24.02 +2.3%	$33.33 +38.8%	+298.9%	$2.03B	$123.67M	N/A	90	Positive News
ADMA ADMA Biologics	4.7439 of 5 stars	$8.70 -0.6%	$18.67 +114.7%	-52.2%	$2.02B	$509.86M	12.79	530	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EIKN) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eikon Therapeutics (EIKN) Competitors

EIKN vs. PVLA, AMLX, GLUE, ADMA, and RAPP

How does Eikon Therapeutics compare to Palvella Therapeutics?

Summary

How does Eikon Therapeutics compare to Amylyx Pharmaceuticals?

Summary

How does Eikon Therapeutics compare to Monte Rosa Therapeutics?

Summary

How does Eikon Therapeutics compare to ADMA Biologics?

Summary

How does Eikon Therapeutics compare to Rapport Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eikon Therapeutics (EIKN) Competitors

EIKN vs. PVLA, AMLX, GLUE, ADMA, and RAPP

How does Eikon Therapeutics compare to Palvella Therapeutics?

Is PVLA or EIKN more profitable?

Do analysts recommend PVLA or EIKN?

Does the media refer more to PVLA or EIKN?

Do insiders & institutionals hold more shares of PVLA or EIKN?

Which has stronger valuation and earnings, PVLA or EIKN?

Summary

How does Eikon Therapeutics compare to Amylyx Pharmaceuticals?

Does the media refer more to AMLX or EIKN?

Do analysts rate AMLX or EIKN?

Which has higher valuation & earnings, AMLX or EIKN?

Do insiders & institutionals believe in AMLX or EIKN?

Is AMLX or EIKN more profitable?

Summary

How does Eikon Therapeutics compare to Monte Rosa Therapeutics?

Does the media favor GLUE or EIKN?

Which has higher earnings & valuation, GLUE or EIKN?

Do insiders and institutionals believe in GLUE or EIKN?

Do analysts prefer GLUE or EIKN?

Is GLUE or EIKN more profitable?

Summary

How does Eikon Therapeutics compare to ADMA Biologics?

Do insiders & institutionals hold more shares of EIKN or ADMA?

Which has better valuation & earnings, EIKN or ADMA?

Do analysts prefer EIKN or ADMA?

Is EIKN or ADMA more profitable?

Does the media prefer EIKN or ADMA?

Summary

How does Eikon Therapeutics compare to Rapport Therapeutics?

Which has preferable valuation and earnings, EIKN or RAPP?

Does the media favor EIKN or RAPP?

Do analysts recommend EIKN or RAPP?

Is EIKN or RAPP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools